NIVOLUMAB: CLINICAL EXPERIENCE IN A TERTIARY HOSPITAL
Gutiérrez Lorenzo M, Alcaraz Sánchez JJ, Mora Rodríguez B, Muñoz Castillo I.
Hospital Pharmacy Service. Hospital Regional Universitario de Málaga, Avenida Carlos Haya S/N

Purpose
To evaluate the effectiveness and safety of patients treated with nivolumab in our hospital.

Material and methods
To evaluate the effectiveness and safety of patients treated with nivolumab in our hospital. Retrospective observational study of all patients treated with nivolumab from February 2016 to June 2017.

Data collected
Clinical history

<table>
<thead>
<tr>
<th>Age</th>
<th>ECOG</th>
<th>Prior lines treatment</th>
<th>% death</th>
<th>Sex</th>
<th>Treatment duration</th>
<th>PFS and OS (Kaplan-Meier)</th>
<th>% adverse effects</th>
<th>Diagmosis</th>
<th>Number of cycles</th>
<th>% patients continuing treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results

**Melanoma**
- Nº patients: 20
- Median disease stage: 4
- Median ECOG: 1
- Mean treatment duration (days): 118
- Median nº (cycles): 8.4
- Line: nº patients
  - First line: 12
  - Second-third line: 8

**NSCLC**
- Nº patients: 20
- Median disease stage: 4
- Median ECOG: 1
- Mean treatment duration (days): 129
- Median nº (cycles): 9.2
- Line: nº patients
  - Second-third line: 20

**RCC**
- Nº patients: 1
- Median disease stage: 4
- Median ECOG: 0
- Mean treatment duration (days): 70
- Median nº (cycles): 5
- Line: nº patients
  - Second line: 1

<table>
<thead>
<tr>
<th>Melanoma</th>
<th>NSCLC</th>
<th>RCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>% patients continuing treatment</td>
<td>20</td>
<td>35</td>
</tr>
<tr>
<td>% deaths</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>Median PFS (95% CI) (days)</td>
<td>74 (38-86)</td>
<td>76 (41-87)</td>
</tr>
<tr>
<td>Median OS (95% CI) (days)</td>
<td>96 (45-120)</td>
<td>99 (67-126)</td>
</tr>
</tbody>
</table>

- 63,4% patients → Toxicity grade I-II
  - 24% asthenia
  - 14,6% pruritus and dermatological reactions
  - 9,7% artralgia or myalgia
  - 15,1% others

Conclusions
The effectiveness in terms of PFS and OS was more reduced than clinical essays, although we should consider that there were patients with ECOG ≥2. In most cases, nivolumab was safe and well tolerated. To evaluate efficacy and long term safety, a longer monitoring period is required.